"Multiple myeloma is diagnosed, chemo isn't working well, and we're worried about resistance—are there any new options?" MM is common in ages 55–65; China sees about 35,000–40,000 new cases yearly. Kisqali (ribociclib), a CDK4/6 inhibitor, is approved for breast cancer but has shown potential in relapsed/refractory MM, offering new hope for some patients.
Multiple myeloma (MM) is a malignancy from abnormal plasma cells in the bone marrow. Typical features: bone damage, anemia, kidney impairment, hypercalcemia, infection and bleeding tendency; some have no early symptoms. Untreated advanced disease can be fatal within 6 months; combination therapy can achieve ~80–95% response and ~15–50% complete remission. Main challenges: traditional chemo has significant side effects (hair loss, nausea, myelosuppression); resistance is common, with relapse/refractory patients in a "remission–relapse–relapse" cycle; many targeted drugs exist and patients struggle to know which fits. Kisqali as a targeted agent acts more precisely on tumor targets, reduces damage to normal cells, and may help with resistance; it is being studied in MM.
Kisqali (ribociclib) is an oral CDK4/6 inhibitor. It blocks tumor cell growth and division by inhibiting CDK4/6, thus controlling progression. CDK4/6 act like a "switch" for tumor growth; Kisqali turns it off so abnormal plasma cells stop proliferating, with less harm to normal cells. It is mainly approved for HR+/HER2- breast cancer; exploratory use in MM combinations has shown potential benefit, especially in some patients refractory to proteasome inhibitors (e.g. ixazomib).
Kisqali is not yet approved for routine MM treatment, but early studies show promise. In exploratory work, Kisqali plus dexamethasone and lenalidomide in 30 relapsed/refractory patients: ORR 46.7%, including 2 complete responses, median PFS 8.2 months; combination was more effective than single agents with manageable toxicity. Case: 68-year-old with MM for 3 years, prior bortezomib and ixazomib, multiple relapses and severe neuropathy; switched to Kisqali plus dexamethasone—by 2 cycles bone pain improved and marrow plasma cells fell from 38% to 12%; by 4 cycles partial response, no severe side effects, stable at 6 months.
Eligible: relapsed/refractory MM, especially those refractory to proteasome inhibitors (bortezomib, ixazomib) or immunomodulatory drugs (lenalidomide) and unable to tolerate intensive chemo; some high-risk newly diagnosed MM may use it as part of a combination per physician. Dosing: 600 mg orally once daily (3×200 mg tablets), 21 days on / 7 days off, 28-day cycle; take at same time each day (fasting or with food), swallow whole; regular CBC and liver function, dose adjustments (e.g. 600→400→200 mg) per doctor—do not self-adjust. Side effects: neutropenia (~62.5%)—weekly CBC, G-CSF if needed, avoid infection, fever means seek care; nausea/vomiting/diarrhea—antiemetic, light diet, fluids, report if diarrhea >3/day; fatigue, hair loss (reversible); headache/back pain, elevated liver enzymes—rest, monitor LFTs, avoid alcohol. Severe effects (jaundice, abdominal pain, QT prolongation) require immediate stop and medical care.
(1) Pre-treatment assessment: bone marrow, CBC, liver/kidney function, FISH, imaging; doctor assesses stage, fitness and resistance to decide if Kisqali is suitable and which combination (e.g. Kisqali+dexamethasone, Kisqali+lenalidomide+dexamethasone). (2) Take as prescribed: fixed daily time, do not stop, reduce or skip; if a dose is missed, do not double the next day. (3) Regular follow-up: weekly CBC, every 2 cycles liver/kidney, marrow and imaging; report side effects. (4) Home care: high-protein, vitamin-rich, digestible diet; avoid intense exercise to prevent fracture; light activity and emotional support.
Is it curative? MM is not curable; Kisqali aims to control disease, relieve symptoms, extend survival and improve quality of life; some achieve long-term stability or deep response. How long to take? Individual; no set duration—continue while stable and tolerated until progression or intolerance, then doctor reassesses. Cost and insurance? Kisqali is mainly approved for breast cancer; use in MM is exploratory and often not reimbursed; ask about patient assistance. Can I take herbs or supplements? Not recommended without doctor approval—interactions and liver/kidney burden possible. What if it doesn't work? If no response or progression after 2–3 cycles, see doctor for reassessment; options may include changing combination (e.g. lenalidomide to thalidomide), other targeted therapy (bispecifics, CAR-T), dose change or other regimens (chemo, transplant)—doctor will decide.
MM is hard to cure but targeted options are growing. Kisqali (ribociclib) as a CDK4/6 inhibitor has shown benefit and acceptable safety in exploratory MM use, offering new hope for relapsed/refractory patients. Treatment plan must be decided by a hematologist/oncologist; do not buy or take the drug on your own. This guide is for information only. We wish every patient clarity and a longer, better quality of life.
More CancerCura and care knowledge